ICS 3131-88 21 July 1988

123

MEMORANDUM FOR:	Director, Intelligence Community Staff Deputy Director, Intelligence Community Staff Coil 6	-SR
FROM:	Special Assistant	25 X 1
SUBJECT:	Drug Science and Technology Special Committee	25 X 1
(Attachment A).	ed, in absence, the first meeting of subject Committee Lt Gen Olmstead chaired the meeting and passed out the ve paper (Attachment B).	25X1 25X1
2. These wo	rking groups or subcommittées are being formed:	
- o <u>=</u> Cont	raband Working Group chaired by Customs.	
_o Comm	unications Working Group chaired by the Coast Guard.	
(Lt T	ram and Requirements Working Group chaired by ICS Gen Olmstead said that this was previously agreed upon with CS taking the lead).	
selected to prov	to be represented on all three working groups. DoD was ide a deputy for the Program and Requirements Working Group. on was made that this working group interface with the	25X1
		25X1
structure, objec nomination or ne	<pre>lmstead has requested comments/suggestions on the Committee tives, scope, etc., by COB 26 July. Also requested is a gative reply for a permanent staff member for the Committee</pre>	
(recommend negat	ive reply).	25X1
working group le plan for their p provide an upd <u>at</u>	meeting will probably be in late August. At that session, aders will be expected to articulate goals/objectives and game articular subcommittees. Also, all attendees will be asked to e of all drug related R&D being carried out by their parent	
organization.		25X1
Attachments A. Memo from B. Objective	Lt Gen Olmstead Paper	25X1

25X1

Distribution

ICS 3131-88

SUBJECT: Drug Science and Technology Special Committee

Copy 1 - D/ICS w/atts

2 - DD/ICS w/atts

3 - SA/D/ICS Chrono w/atts

4 - SA/D/ICS Subject file w/atts

5 - IC Registry w/atts

SA/D/ICS/ 7/19/88

25X1



NATIONAL DRUG POLICY BOARD Washington, D.C. 20530



2 9 JUN 1988

C-	ГΛ	т
J	ı /~	١l

STAT

STAT

Deputy Director

Intelligence Community Staff

Washington, D.C. 20505

Dear

STAT

You have been identified as your agency's representative to the National Drug Policy Board's Science and Technology (S&T) Committee. The first meeting of the S&T Committee will convene at 10:00 a.m., Tuesday, 19 July in Room 3C200, the Pentagon. Your attendance will be critical as we commence our endeavor to dramatically enhance the level of science and technology support available to drug law

Procedures for entering the Pentagon should be arranged with Nancy Harper of my staff, at 695-7804.

I look forward to working with you.

enforcement and demand reduction agencies.

Sincerely,

Stephen G. Olmstead Lieutenant General, USMC

Chairman, Science and

Technology Committee

DRUG SCIENCE AND TECHNOLOGY SPECIAL COMMITTEE

Committee Objectives

The goal of the Committee is to enhance the effectiveness and efficiency of all agencies in acquiring new technology for drug law enforcement.

Objectives include:

- * Establish valid technology requirements considering function, operational requirements, and compatability as well as specific technology user.
- * Identify potential technology currently being developed for other purposes, as well as technology being developed for drug enforcement.
- * Marry current and potential technology to requirements.
- * Marry agencies with mutual technology interests to focus resources and development programs.
- * Ensure development of a technology knowledge base that includes the agencies, academia, and industry, and is based on requirements and capability, not marketing goals.
- * Establish an order of programs based on requirements and technology that will provide the best return on investment.
- * Establish a larger, better-defined, and more collective market for industry to spur greater industry investment, more responsive technology, and better costs based on larger quantity procurement.

The measurable results of Committee operations should include the faster acquisition of technology that will make a significant difference in drug law enforcement, and a more efficient and economical utilization of resources expended on technology development and acquisition.

Committee Scope

The scope of Committee interest is science and technology that supports efforts to detect and suppress the flow of illegal drugs and aids programs to reduce demand. The Committee will advise and coordinate in areas pertaining to technology development, acquisition, exploitation, awareness, and evaluation.

Committee working groups will focus on areas or issues of major concern with respect to the application of technology. These functionally-ordered working groups will include representatives from the enforcement and prevention organizations, the civil sector, and academia, as appropriate.

Initial working groups will focus on defining and ordering technology requirements, detection of contraband in containers, and establishing interoperable communications.

DRUG SCIENCE AND TECHNOLOGY SPECIAL COMMITTEE

Funding Requirements

Start-up funding will be required by the Committee for:

- * Initial contractor support to design and initiate an automated drug science and technology data base to include requirements, on-going projects, and other R&D of potential value; and to identify appropriate contacts in industry and academia.
- * Staff assistant support to include computer and other equipment, publication and data base subscriptions, and travel.
- * Meetings of industry, academia, and the law enforcement community to describe requirements and on-going work, propose technological approaches, and identify specific projects of potential value.

Continuing funding will be required for:

- * Contractor support including maintenance of data base.
- * Newsletter or other means of disseminating technology requirements and interests of law enforcement agencies.
- * Continued industry liaison; also meetings with foreign law enforcement agencies and research organizations.
- * Demonstrations of potential technology under field conditions.
- * Administrative support including staff assistant.

Funding Sources

The Committee will establish a funding plan and estimated level of funding requirements. It is expected that funding needs will be absorbed by the Committee participants after the plan is approved. Committee funds would be held in a separate account at Treasury.

The start-up requirements described above are estimated to cost \$ 300,000 to \$ 400,000. Annual costs are estimated at \$ 750,000 to \$ 1,000,000 if current expectations for major increases in funding for drug R&D are realized. However, funding requirements could be scaled down considerably if agency R&D funding levels were lower.

It should be noted that the above actions by the Committee would reduce or eliminate the need for individual agencies to conduct similar activities at their own expense; i.e., it would replace and make more efficient current expenditures for similar purposes.

The Committee has an immediate requirement for seed money to begin start-up activities until such time as the funding plan is approved and funds are provided by the participating agencies. The sum of \$ 200,000 has been requested to enable the Committee to begin its activities.

Declassified in Part - Sanitized Copy Approved for Release 2012/11/09: CIA-RDP90M00551R001600840013-8